A simple method for quantifying functional selectivity and agonist bias.
暂无分享,去创建一个
Arthur Christopoulos | Steven J Novick | Steven J. Novick | Terry Kenakin | T. Kenakin | A. Christopoulos | Vanessa M Muniz-Medina | Vanessa Muniz-Medina | C. Watson | Christian Watson | Steven Novick | Vanessa M. Muniz-Medina
[1] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[2] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[3] J S Ward,et al. Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles. , 1995, Journal of medicinal chemistry.
[4] R P STEPHENSON,et al. A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.
[5] Terry Kenakin,et al. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. , 2007, Trends in pharmacological sciences.
[6] Sadashiva S Karnik,et al. Multiple Signaling States of G-Protein-Coupled Receptors , 2005, Pharmacological Reviews.
[7] Clay W Scott,et al. Evaluating Cellular Impedance Assays for Detection of GPCR Pleiotropic Signaling and Functional Selectivity , 2009, Journal of biomolecular screening.
[8] Terry Kenakin,et al. Drug efficacy at G protein-coupled receptors. , 2002, Annual review of pharmacology and toxicology.
[9] R. Zimlichman,,et al. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. , 1996, European journal of pharmacology.
[10] M. Bouvier,et al. Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy , 2006, Molecular Pharmacology.
[11] H. Rang. STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE. , 1964, British journal of pharmacology and chemotherapy.
[12] B. Roth,et al. Multiple mechanisms of serotonergic signal transduction. , 1987, Life sciences.
[13] T. Kenakin. '7TM receptor allostery: putting numbers to shapeshifting proteins. , 2009, Trends in pharmacological sciences.
[14] Laurence J. Miller,et al. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.
[15] Qin Wang,et al. Regulation of α2AR trafficking and signaling by interacting proteins , 2007 .
[16] Arthur Christopoulos,et al. Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias* , 2010, The Journal of Biological Chemistry.
[17] John P. Moore,et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. , 2007, Virology.
[18] J. Violin,et al. β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .
[19] R. Mailman. GPCR functional selectivity has therapeutic impact. , 2007, Trends in pharmacological sciences.
[20] Thomas A Kost,et al. Implementation of BacMam virus gene delivery technology in a drug discovery setting. , 2007, Drug discovery today.
[21] G. Milligan,et al. Deconvolution of complex G protein–coupled receptor signaling in live cells using dynamic mass redistribution measurements , 2010, Nature Biotechnology.
[22] David R. Sibley,et al. Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.
[23] F. Ehlert. Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.
[24] B. Rovin,et al. The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .
[25] R. Lefkowitz,et al. Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor* , 2009, Journal of Biological Chemistry.
[26] J. Black,et al. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation , 1985, British journal of pharmacology.
[27] H. Loh,et al. Interaction of delta-opioid receptors with multiple G proteins: a non-relationship between agonist potency to inhibit adenylyl cyclase and to activate G proteins. , 1994, Molecular pharmacology.
[28] F. Ehlert,et al. Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes , 2009, Journal of Pharmacology and Experimental Therapeutics.
[29] Terry Kenakin,et al. Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.
[30] L. Luttrell. Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity , 2007, Journal of Molecular Neuroscience.
[31] L. Limbird,et al. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. , 2002, Cellular signalling.
[32] P. Sexton,et al. G‐Protein‐coupled receptor–protein interactions: Basis for new concepts on receptor structure and function , 2005, Clinical and experimental pharmacology & physiology.
[33] C. Breivogel,et al. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. , 2000, Molecular pharmacology.
[34] M. Matsui,et al. Estimation of Relative Microscopic Affinity Constants of Agonists for the Active State of the Receptor in Functional Studies on M2 and M3 Muscarinic Receptors , 2009, Molecular Pharmacology.
[35] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.